Table 3.

MDASI Symptom Severity at End of First Cycle of Chemotherapy and Univariate Analysis of Symptom Increase^* as Predictors of Overall Survival (n = 59)

	Symptom Severity at End of First Cycle of Chemotherapy		Cox Proportional Hazard Regression Model for Symptom Increase*
Variable	Mean† (SD)	% with Symptom Increase*	Participants/Events	HR	95% CL
Fatigue	3.32 (2.45)	49.2	59/49	2.405‡	1.324	4.368
Shortness of breath	2.57 (2.64)	34.5	58/48	2.295§	1.190	4.425
Vomiting	0.36 (1.00)	19.0	58/48	2.213§	1.036	4.727
Difficulty remembering	1.60 (2.13)	34.5	58/48	2.167§	1.182	3.970
Numbness	1.38 (2.26)	33.3	57/47	2.080§	1.115	3.880
Lack of appetite	1.76 (2.37)	25.9	58/48	2.067§	1.057	4.044
Nausea	0.90 (1.93)	31.0	58/48	1.886	0.982	3.621
Constipation	1.41 (2.32)	24.5	53/43	1.884	0.904	3.927
Disturbed sleep	2.17 (2.20)	42.4	59/49	1.408	0.773	2.564
Drowsiness	2.17 (2.13)	37.9	58/48	1.395	0.764	2.548
Coughing	1.66 (1.77)	34.5	58/48	1.393	0.755	2.570
Sadness	1.69 (2.49)	34.5	58/48	1.367	0.740	2.523
Dry mouth	1.95 (2.36)	34.5	58/48	1.299	0.705	2.395
Distress	2.05 (2.53)	34.5	58/48	1.231	0.661	2.293
Pain	2.49 (2.54)	39.0	59/49	1.030	0.570	1.863

MDASI indicates M. D. Anderson Symptom Inventory; SD, standard deviation; HR, hazard ratio; CL, confidence limit

^*“Symptom increase” was defined as a symptom-score increase of 1 or more points on the MDASI’s 0–10 scale between baseline and the end of the first chemotherapy cycle (21 days, on average).

^†Mean symptom severity score, MDASI 0–10 scale.

^‡Significant at P <.01.

^§Significant at P < .05.